Our focus on expanding our market presence within the biopharmaceutical sector has been beneficial. We've witnessed strong uptake of our automated systems, which is reflected in our revenue growth.
— CEO, Mesa Laboratories
03Detailed Report
MLAB
Mesa Laboratories Inc
Period
Q3 2025
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 25, 2026
Swipe to view all report sections
Executive Summary
Mesa Laboratories Inc reported a revenue of $62.84 million for Q3 2025, marking a significant year-over-year increase of 17.52% and a quarter-over-quarter rise of 8.66%. However, despite this encouraging revenue growth, the company faced substantial profitability challenges, posting a net loss of $1.68 million, which translates to an EPS of -$0.31. Management acknowledged these hurdles during the earnings call, indicating that operational inefficiencies and increased costs have been critical factors in impacting overall profitability.
Despite the challenges, the company's strong revenue growth showcases its resilience and highlights the effectiveness of its strategic initiatives in expanding market share, particularly in the biopharmaceutical and sterilization segments. Mesa remains focused on improving operational efficiency and navigating through its current financial difficulties while enhancing value for shareholders in the long term.
Key Performance Indicators
Revenue
Increasing
62.84M
QoQ: 8.66% | YoY: 17.52%
Gross Profit
Increasing
39.75M
63.26% margin
QoQ: 12.13% | YoY: 19.02%
Operating Income
Increasing
5.78M
QoQ: 64.74% | YoY: 8 725.37%
Net Income
Decreasing
-1.68M
QoQ: -148.89% | YoY: -179.21%
EPS
Decreasing
-0.31
QoQ: -149.21% | YoY: -179.49%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue Metrics:
- Revenue: $62.84 million (YoY: 17.52%, QoQ: 8.66%)
- Gross Profit: $39.75 million (YoY: 19.02%, QoQ: 12.13%)
- Operating Income: $5.78 million (YoY: 8,725.37%, QoQ: 64.74%)
- Net Income: -$1.68 million (YoY: -179.21%, QoQ: -148.89%)
Operational Expenses:
- Operating Expenses: $33.98 million
- Research and Development Expenses: $5.05 million
- Selling and Marketing Expenses: $10.45 million
Liquidity Ratios:
- Current Ratio: 0.711
- Quick Ratio: 0.531
- Cash at End of Period: $30.96 million
Management noted the importance of controlling operational costs to improve profitability while continuing investments in R&D to drive future growth.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
62.84M
17.52%
8.66%
Gross Profit
39.75M
19.02%
12.13%
Operating Income
5.78M
8 725.37%
64.74%
Net Income
-1.68M
-179.21%
-148.89%
EPS
-0.31
-179.49%
-149.21%
Key Financial Ratios
Gross Profit Margin
Excellent
63.30%
Gross profit margin is exceptional, indicating strong pricing power and operational efficiency
Operating Profit Margin
Fair
9.20%
Operating margin is moderate, room for improvement in cost management
Net Profit Margin
Weak
-0.03%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
0.00%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.01%
Return on equity suggests inefficient capital allocation
Current Ratio
Concern
0.71
Current ratio below safe levels, potential liquidity risk
Debt to Equity
High Risk
1.36
Debt-to-equity indicates high leverage and elevated financial risk
P/E Ratio
Negative
-106.79x
Negative earnings make P/E ratio not meaningful
Price to Book
Premium
4.61x
Trading at premium to book value, reflects strong intangibles or growth
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.